Molecules responsible for radio-resistant glioblastoma identified
(Hokkaido University) Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 30, 2020 Category: Biology Source Type: news

An area of the brain where tumor cells shelter from chemotherapy in childhood leukaemia
(Universidad Complutense de Madrid) Sometimes, the central nervous system harbours tumour cells that elude treatment and thus become one of the main sources of relapse. Research led by the Complutense University of Madrid has identified one of these locations in which the cells remain protected: the stroma of the choroid plexus, a structure in the brain ventricles responsible for the production of cerebrospinal fluid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2020 Category: International Medicine & Public Health Source Type: news

MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2020 Category: Cancer & Oncology Source Type: news

Radiosurgery Appears to Benefit Old & Young With Brain Metastases Radiosurgery Appears to Benefit Old & Young With Brain Metastases
Stereotactic radiosurgery provides similar overall survival in patients older and younger than 75 years who have brain metastases from lung cancer, according to a retrospective study from Japan.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 22, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

RANZCR releases AI practice standards for radiology
The Royal Australian and New Zealand College of Radiologists (RANZCR) has issued...Read more on AuntMinnie.comRelated Reading: RANZCR appoints interim CEO Australians urge radiology access to protective gear RT improves elderly brain cancer patient survival Intelerad to launch enterprise software at RANZCR 2019 RANZCR issues final version of ethical AI guidelines (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 21, 2020 Category: Radiology Source Type: news

Penn researchers discover potential cause of immunotherapy-related neurotoxicity
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news

PET shows promise for detecting NSCLC recurrence
F-18 FDG PET/CT shows promise for detecting recurrence of disease in non-small...Read more on AuntMinnie.comRelated Reading: PET radiomics tailor head/neck cancer treatment Nuclear medicine volume plummets due to COVID-19 Dual-phase technique improves PET/CT brain tumor imaging PET/CT could be useful for diagnosing fever PET/MRI ups lesion detection by 15% for some cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

NIH funds research into differences in glioblastoma between males and females
(Cleveland Clinic) A team led by researchers from Case Western Reserve University School of Medicine and Cleveland Clinic Lerner Research Institute has secured $10.4 million over five years from the National Institutes of Health/National Cancer Institute to explore at the molecular level the differences in glioblastoma between males and females. The researchers will delve into the genetics, epigenetics and cell biology of glioblastoma - the most common and deadliest brain tumor in adults - to better understand the physiologic processes which may lead to more personalized therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

Spotting breast cancer's spread to the brain before symptoms start could improve survival
(European Organisation for Research and Treatment of Cancer) Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

PET agent shows promise for imaging lung inflammation
An experimental PET imaging agent shows promise for imaging inflammation in...Read more on AuntMinnie.comRelated Reading: FET-PET offers more info on treatment of brain metastases PET radiomics tailor head/neck cancer treatment Nuclear medicine volume plummets due to COVID-19 Dual-phase technique improves PET/CT brain tumor imaging PET/CT could be useful for diagnosing fever (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 16, 2020 Category: Radiology Source Type: news

FET-PET offers more info on treatment of brain metastases
Using PET with the radiolabeled amino acid F-18 fluoroethyl-tyrosine (F-18-FET)...Read more on AuntMinnie.comRelated Reading: FET-PET can be useful for glioma evaluations FET-PET adds 'relevant' info to pediatric cancer cases SNMMI: FET-PET could have answers for brainstem glioma SNMMI: FET-PET aids pediatric brain cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 14, 2020 Category: Radiology Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Media News - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Investor Update - September 11, 2020 Category: Pharmaceuticals Source Type: news

Feeding off fusion or the immortalization of tumor cells
(IMBA- Institute of Molecular Biotechnology of the Austrian Academy of Sciences) Despite all recent progress, cancer remains one of the deadliest human diseases. In a new publication that appeared in the journal Cell, researchers from J ü rgen Knoblich's lab at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences - found a very surprising and unexpected connection between the formation of tumors and mitochondria, the power house of the cells, that allows neural stem cells that normally build our brain to become deadly tumor cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 11, 2020 Category: Biology Source Type: news

FDA Clears New Neurosurgical Port for Deep Brain Access FDA Clears New Neurosurgical Port for Deep Brain Access
The FDA has cleared MindsEye (Minnetronix Medical), the first minimally invasive, expandable and retractable port that allows deep brain access to treat stroke, cancer, and other conditionsFDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2020 Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Alert Source Type: news

PET radiomics tailor head/neck cancer treatment
Radiomic factors -- that is, image-based tumor phenotypes -- gleaned from F-18...Read more on AuntMinnie.comRelated Reading: Dual-phase technique improves PET/CT brain tumor imaging PET/CT could be useful for diagnosing fever PET/MRI ups lesion detection by 15% for some cancers Radiomics can predict treatment outcome for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 10, 2020 Category: Radiology Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

How loss of single gene fuels deadly childhood brain cancer
(University of California - San Diego) UC San Diego researchers describe how the functional loss of a single gene negatively impacts neural development and promotes the growth of a particularly deadly form of pediatric brain cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 10, 2020 Category: Biology Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Media News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Investor Update - September 9, 2020 Category: Pharmaceuticals Source Type: news

Dual-phase technique improves PET/CT brain tumor imaging
Using a dual-phase technique with F-18 FDG PET/CT -- that is, performing the...Read more on AuntMinnie.comRelated Reading: PET/CT could be useful for diagnosing fever SNMMI 2020: PSMA-PET/CT changes prostate cancer management SNMMI 2020: PET tracer could image, treat glioblastoma PET/CT confirms breast cancer predicted by blood markers New PET/CT tracer reliably detects prostate cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 3, 2020 Category: Radiology Source Type: news

Long sick leave after low-grade brain tumor
(University of Gothenburg) One year after the diagnosis of low-grade malignant brain tumor, a University of Gothenburg study shows, just under three people in ten were in full-time employment. Another year later, the proportion remained below half. For this young patient group, returning to work is a key health factor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news

Brain tumor drug receives rare disease designations from the FDA
(Oklahoma Medical Research Foundation) The Food and Drug Administration has given Orphan Disease Designation and Rare Pediatric Disease Designation to OKN-007, an experimental brain cancer treatment currently in Phase 2 clinical trials at eight U.S. sites. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 2, 2020 Category: Cancer & Oncology Source Type: news

MSK study links inflammation to Alzheimer's disease development
(Memorial Sloan Kettering Cancer Center) Scientists at the Sloan Kettering Institute have discovered a direct link between the immune response to viruses and bacteria and the development of plaques in the brain that characterize Alzheimer's disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 2, 2020 Category: Biology Source Type: news

NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructu...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial
(NRG Oncology) A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 31, 2020 Category: Cancer & Oncology Source Type: news

FEFU scientists are developing genetic methods to understand malignant tumors
(Far Eastern Federal University) Scientists of Far Eastern Federal University (FEFU University) get started studying the formation and survival mechanisms of the brain malignant tumors cells, i.e. glioma, to reveal new ways for diagnosis and therapy for this fatal disease. This research was supported by the grant from Russian Science Foundation (RSF). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 31, 2020 Category: Cancer & Oncology Source Type: news

Sex cells have a sweet tooth, and they pass it on to the brain
(Champalimaud Centre for the Unknown) Scientists discover that a small group of sex cells instruct a fundamental behavioural change in the female fruit fly - developing a sweet tooth. These findings prompt new investigation into dietary strategies for preventing age-related fertility decline and cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 31, 2020 Category: Cancer & Oncology Source Type: news

Researchers find potential to make brain cancers in children respond better to treatment
(McMaster University) Research has identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, making these aggressive forms of cancer more responsive to therapies. The work also found the Wnt pathway, which has historically been considered cancer-promoting, to function as a cancer inhibitor in certain contexts. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 28, 2020 Category: Cancer & Oncology Source Type: news

Researchers identify mechanism underlying cancer cells' immune evasion
(Rockefeller University Press) Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 27, 2020 Category: Cancer & Oncology Source Type: news

New therapy targets breast cancer metastases in brain
(Northwestern University) When breast cancer spreads to the brain, the prognosis is grim. Patients only have about six months to live. Women with HER2-positive breast cancer tend to develop brain metastases in up to 55% of cases. Chemotherapy drugs targeting breast cancer cells in the brain aren't effective, because they can't cross the blood-brain-barrier. But a new combination therapy targeting breast cancer tumors in the brain dramatically decreased tumor size and increased survival in a preclinical study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Imaging Biometrics added to Arterys marketplace
Advanced visualization software firm Imaging Biometrics has partnered with...Read more on AuntMinnie.comRelated Reading: Imaging Biometrics touts IB-Neuro recognition Imaging Biometrics secures $2.57M grant AI Metrics joins forces with Imaging Biometrics Imaging Biometrics nets NIH grant Imaging Biometrics points to brain tumor study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 25, 2020 Category: Radiology Source Type: news

Cognitively impaired kids undergo more CT for appendicitis
Children who have developmental difficulties undergo CT for suspected appendicitis...Read more on AuntMinnie.comRelated Reading: AI algorithm detects appendicitis on CT exams in ER Academic pediatric facilities have lower CT radiation dose CT scans may be linked to brain cancer in kids CT dose tracking highlights differences among kids in ER Kids get more CT radiation at nonpediatric hospitals (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 24, 2020 Category: Radiology Source Type: news

Drugs against alpha-ketoglutarate may combat deadly childhood brain tumor
NIH funded pre-clinical study highlights intricate links between brain tumors and cancer. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 18, 2020 Category: American Health Source Type: news

Some Coronavirus Patients Are Reporting Symptoms That Last Months. Nobody Knows Exactly How to Treat Them
Kayla Brim laughed when she learned it could take 10 days to get her COVID-19 test results back. “I thought, ‘Okay, well, within 10 days I should be fine,’” she remembers. That was on July 2. More than a month later, Brim is still far from fine. Prior to the pandemic, the 28-year-old from Caldwell, Idaho, juggled homeschooling her two kids with her work as a makeup artist—she was supposed to open her own salon in July. Now, she suffers daily from shortness of breath, exhaustion, excruciating headaches, brain fog, neuropathy, high blood pressure and loss of taste and smell. She feels like &ldqu...
Source: TIME: Health - August 18, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news

Drugs against alpha-ketoglutarate may combat deadly childhood brain tumor
(NIH/National Institute of Neurological Disorders and Stroke) Every year, 150 to 300 children in the United States are diagnosed with diffuse intrinsic pontine gliomas (DIPGs), aggressive and lethal tumors that grow deep inside the brain, for which there are no cures. In a study funded by the National Institutes of Health, researchers showed that experimental drugs designed to lower the body's natural production of alpha-ketoglutarate extended the lives of mice harboring DIPG tumors by slowing the growth of the cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2020 Category: Cancer & Oncology Source Type: news

Gene targeting helps overcome the resistance of brain cancer to therapy
(McGill University) New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma. A McGill-led study published in Nature Communication reveals that suppressing the OSMR gene can improve the effectiveness of radiation therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2020 Category: International Medicine & Public Health Source Type: news

Pink drink is helping surgeons spot aggressive brain cancers... by making tumours 'glow in the dark'
The innovation, now being used by neurosurgeons across the UK, doubles the chances doctors will find - and remove - all the cancer, halting progression of the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - August 15, 2020 Category: Consumer Health News Source Type: news

Controlling nutritional status score and prognostic nutrition index predict the outcome after severe traumatic brain injury - Li Y, Liu C, Luo X, He Q, Cheng Y, Shen W, Xie Z.
OBJECTIVES: Immune-nutritional status is correlated with a clinical outcome in critical illness. Recently, controlling nutritional status (CONUT) score and prognostic nutrition index (PNI) has been reported to predict prognosis following cancer and other d... (Source: SafetyLit)
Source: SafetyLit - August 14, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Study suggests new potential approach against fatal childhood brain cancer
(Michigan Medicine - University of Michigan) In mouse models of DIPG, a fatal childhood brain cancer, simultaneously attacking two metabolic pathways led to significant improvements in survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2020 Category: International Medicine & Public Health Source Type: news

FEFU scientists propose to restore neural tissue with hydrogels based on modified pectins
(Far Eastern Federal University) Far Eastern Federal University (FEFU) scientists have developed implantable hydrogels based on plant polysaccharides (pectins). They can play the role of an artificial extracellular matrix, a special network of molecules that fills the space between body cells. The development to be used as a medium for growing tissues and organs, as well as for drug delivery and brain recovery after removal of malignant tumors glioblastomas. A related article appears in the International Review of Neurobiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2020 Category: International Medicine & Public Health Source Type: news

Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news

Scientists found genes that help cancer cells to penetrate the brain
(Sechenov University) An international team of scientists, including a researcher from Sechenov University, reviewed scientific articles on proteins (and genes encoding them) that help cancer cells enter the brain. An understanding of the processes that facilitate the formation of metastases in the brain will allow scientists to create new methods for cancer diagnosis and treatment. Details of the study can be found in the journal Trends in Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

The structural basis of Focal Adhesion Kinase activation on lipid membranes unravelled
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Patients with glioma - a very common type of tumour originating in the brain - see improvement in survival rates with combined treatment of radiotherapy plus temozolomide* Researchers found a novel mechanism on how tumours evade chemotherapy through genomic rearrangements of the MGMT DNA repair gene* This finding is potentially relevant for updating the methods used to monitor temozolomide efficacy. Genomic rearrangement could be a marker to be detected in blood samples and help make therapeutic decisions (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

Coming to Terms with Unreality
When I was 14 years old, I entered my freshman year of high school feeling nothing but a dull sense of disquietude. I was not happy to be starting the new school year. I was always “the quiet kid”, and that label only rang truer over time, as I retreated further into my shell with each passing school year. I had few friends, and the ones I had were fair-weather, frequently passing up hanging out with me in favor of others. I knew in the back of my mind that I should feel stressed or upset when the year began, but I just felt empty.  My late childhood and early adolescence, meant to be a time of growth and ...
Source: Psych Central - August 6, 2020 Category: Psychiatry Authors: Renee Consorte Tags: Dissociative disorders Personal Stories Adolescence Depersonalization Derealization Dissociation Resentment Social Anxiety Source Type: news

Study: Topical minoxidil reverses hair loss caused by radiation for brain, head, neck cancers
Treatment with topical minoxidil helps restore hair loss caused by radiation treatment for brain tumors and other head and neck cancers, a study published Wednesday by JAMA Dermatology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 5, 2020 Category: Consumer Health News Source Type: news

UCLA launches major mental health study to discover insights about depression
While the capability to diagnose cancer and heart problems has advanced by giant steps in recent years, methods to detect depression have stubbornly stayed the same for more than a century: Observe patients, and ask them how they are doing.UCLA has launched a major new study, sponsored by and in collaboration with Apple, designed to help revolutionize detection and treatment of depression.The three-year study, which begins this week, was co-designed by researchers at UCLA and Apple to obtain objective measures of factors such as sleep, physical activity, heart rate and daily routines to illuminate the relationship between ...
Source: UCLA Newsroom: Health Sciences - August 4, 2020 Category: Universities & Medical Training Source Type: news

A research team of the CNIO and the HKUST identifies how some gliomas develop chemoresistance
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Patients with glioma - a very common type of tumour originating in the brain - see improvement in survival rates with combined treatment of radiotherapy plus temozolomide* Researchers found a novel mechanism on how tumours evade chemotherapy through genomic rearrangements of the MGMT DNA repair gene* This finding is potentially relevant for updating the methods used to monitor temozolomide efficacy. Genomic rearrangement could be a marker to be detected in blood samples and help make therapeutic decisions (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 4, 2020 Category: Cancer & Oncology Source Type: news